BCAX
NASDAQ · Biotechnology
Bicara Therapeutics Inc
$18.22
-0.17 (-0.92%)
Open$18.44
Previous Close$18.39
Day High$18.55
Day Low$17.70
52W High$20.25
52W Low$7.80
Volume—
Avg Volume538.8K
Market Cap1.19B
P/E Ratio—
EPS$-5.03
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-20.4% upside
Current
$18.22
$18.22
Target
$14.50
$14.50
$9.75
$14.50 avg
$19.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 181.36M | 184.14M | 159.71M |
| Net Income | -39,755,825 | -41,476,631 | -32,201,263 |
| Profit Margin | -21.9% | -22.5% | -20.2% |
| EBITDA | -52,674,751 | -54,395,580 | -46,526,832 |
| Free Cash Flow | -41,149,249 | -44,589,211 | -37,987,097 |
| Rev Growth | +5.9% | -5.2% | -5.4% |
| Debt/Equity | 0.58 | 0.56 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |